Price range: 230 € through 650 €

Retatrutide (LY3437943), also known as RT, is an investigational GIP/GLP-1/glucagon triple receptor agonist developed by Eli Lilly. This product configuration contains 10 individual vials specified at 40 mg per vial, providing 400 mg of nominal total content per kit. Retatrutide is being investigated across metabolic and cardiometabolic research areas including obesity, type 2 diabetes, cardiovascular and renal outcomes, metabolic liver disease, obstructive sleep apnea and obesity-associated knee osteoarthritis. For legitimate research purposes; not currently FDA-approved for general public use.